1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A

SSSE:688336
33.76
CNY
+1.26
(+3.88%)
47.59BMarket Cap
Oct 23Next Earn
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A
SSE:688336
(Shanghai Stock Exchange)

Recent

price

33.76

P/E

ratio

- -

div

yld

0.07%

ROIC.AI

2007
2008
2009
2010
2011
2012
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.13
0.22
0.33
0.5
0.63
0.8
1.31
1.49
1.53
1.52
0.77
1.06
0.92
1.14
1.33
4.69
- -
Revenue per Share
0.02
0.08
0.15
0.23
0.26
0.35
0.37
0.52
0.5
0.3
-0.26
0.02
0.06
0.33
0.79
3.24
- -
Basic EPS, GAAP
-0.01
0.03
0.18
0.19
0.13
0.25
0.34
0.22
0.36
0.59
-0.31
-0.58
0.01
0.2
- -
3.12
- -
Free Cash Flow per Basic Share
- -
0.01
0.01
- -
- -
0.02
- -
- -
- -
0.93
- -
- -
- -
- -
0.06
0.09
0.02
Dividend per Share
0.62
0.71
0.9
1.33
1.6
1.94
3.32
3.85
4.35
3.57
5.04
5.08
5.15
5.47
6.23
9.45
9.49
Book Value per Share
0.37
0.46
0.65
1.01
1.28
1.64
2.91
3.42
3.93
3.18
4.7
4.75
4.8
5.16
5.72
8.84
8.86
Tangible Book Value per Share
740
740
740
688
749
740
733
742
744
773
852
873
894
890
896
894
894
Basic Weighted Avg Shares
92
159
245
343
475
596
961
1,103
1,142
1,177
655
929
825
1,014
1,194
4,199
- -
Sales/Revenue/Turnover
5.14
29.73
37.39
39.65
38.27
36.94
30.7
42.02
33.73
16.84
-33.26
-7.89
0.61
20.9
21
75.19
- -
Operating Margin (%)
25
26
29
31
36
42
76
85
120
132
136
135
122
96
128
124
- -
Depreciation Expense
17
62
110
157
196
257
268
389
370
229
-217
18
49
295
705
2,899
- -
Net Income, GAAP
- -
- -
- -
9.47
11.29
10.65
16.8
15.55
12.97
8.37
- -
- -
- -
8.78
2.3
12.86
- -
Effective Tax Rate (%)
18.74
39.17
44.98
45.64
41.31
43.13
27.89
35.23
32.36
19.47
-33.2
1.94
5.97
29.05
59.03
69.05
- -
Profit Margin (%)
128
118
229
511
836
1,020
1,087
1,532
1,906
1,396
2,841
2,656
2,611
1,942
2,343
5,782
5,771
Working Capital
57
30
- -
- -
191
191
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
462
524
666
1,054
1,281
1,539
2,549
2,916
3,276
2,904
4,520
4,539
4,600
4,879
5,537
8,415
8,462
Total Equity
0.4
- -
- -
14.88
12.74
12.56
10.11
13.44
11.68
7.61
- -
- -
- -
6
13.49
40.96
- -
Return on Invested Capital (%)
3.5
- -
- -
18
15.49
15.96
13.07
15.2
11.34
7.15
- -
- -
- -
6.35
13.67
41.53
- -
Return on Capital (%)
3.83
12.67
18.54
18.97
18.13
19.62
13.76
14.64
12.18
7.53
-5.9
0.4
1.08
6.2
13.47
41.36
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
894
896
896
Market Capitalization
36,742
46,715
47,590

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
6,229
6,092
6,006
Cash, Cash Equivalents & STI
1,267
1,475
1,179
Accounts Receivable, Net
150
307
181
Inventories
261
280
292
Total Current Liabilities
447
277
235
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21%
14.66%
51.98%
Free Cash Flow
78,872.95%
157,751.23%
787,491.62%
Net Income, GAAP
82.46%
202.59%
311.49%
Sales/Revenue/Turnover
36.15%
64.61%
251.81%
Total Cash Common Dividend
- -
- -
45.98%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
267
330
343
254
1,194
2025
311
331
- -
3,083
4,199
2026
431
434
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.1
0.04
0.12
0.53
0.79
2025
0.12
0.1
- -
2.8
3.24
2026
0.2
0.22
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.03
0.02
- -
0.06
2025
- -
0.06
- -
0.02
0.09
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. is an innovative biopharmaceutical entity in China, engaged in the comprehensive process of discovering, developing, manufacturing, and commercializing antibody-based therapeutics. The company's key marketed products include YISAIPU, a recombinant fusion protein addressing autoimmune conditions such as rheumatoid arthritis, ankylosing spondylitis, and psoriasis; Jiannipa, a recombinant humanized anti-CD25 monoclonal antibody injection utilized to prevent acute rejection in kidney transplantation; and Inetetamab, an innovative anti-HER2 monoclonal antibody for oncology, notable for being independently developed in China. Sunshine Guojian also maintains a robust research and development pipeline, exploring novel antibody drug candidates for various therapeutic areas, including additional autoimmune disorders, solid tumors, and ophthalmological diseases. With a strong focus on advanced antibody technologies, the company leverages its integrated platforms for global collaborations, such as the partnership with Numab Therapeutics for multi-specific cancer antibodies and the joint development of the PD-1/VEGF bispecific antibody SSGJ-707, which has entered global Phase III clinical trials with Pfizer. Established in 2002, the company operates from its headquarters in Shanghai, China.